Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience

SIMPLE SUMMARY: Chimeric antigen receptor (CAR) T-cell therapies targeting CD19 have greatly improved the outcomes of many B-cell non-Hodgkin lymphomas, including relapsed/refractory large B-cell lymphoma (R/R LBCL). Nevertheless, a significant number of patients do not benefit. In this single-cente...

Descripción completa

Detalles Bibliográficos
Autores principales: Trando, Aaron, Ter-Zakarian, Anna, Yeung, Phillip, Goodman, Aaron M., Hamdan, Ayad, Hurley, Michael, Jeong, Ah-Reum, Tzachanis, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527363/
https://www.ncbi.nlm.nih.gov/pubmed/37760639
http://dx.doi.org/10.3390/cancers15184671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527363/
https://www.ncbi.nlm.nih.gov/pubmed/37760639
http://dx.doi.org/10.3390/cancers15184671

Ejemplares similares